Novocure Ltd
Change company Symbol lookup
Select an option...
NVCR Novocure Ltd
CGNX Cognex Corp
INTC Intel Corp
ZSANQ Zosano Pharma Corp
BIPC Brookfield Infrastructure Corp
UTG Reaves Utility Income Trust
ARDLF Ardent Leisure Group Ltd
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
Go

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Based in Jersey
Company profile

NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.

Closing Price
$79.89
Day's Change
3.11 (4.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
80.27
Day's Low
77.84
Volume
(Light)
Volume:
395,071

10-day average volume:
614,992
395,071

Company Profile

NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
14.75x
Price/Book (MRQ)
18.07x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
6.8M
Previous Month
6.9M
Percent of Float
7.46%
Days to Cover
13.1803 Days

Share Information

NVCR is in a share class of common stock
Float
90.9M
Shares Outstanding
104.7M
Institutions Holding Shares
460
77.91%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in thousands.

Company Officers

  • William F. DoyleChmn.
  • Asaf DanzigerPres.
  • Ashley CordovaCFO
  • Wilhelmus C. M. GroenhuysenCOO
  • William Burke

Address

Insider Trading

During the most recent quarter, 53K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.